Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2-8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, -0.07 to 0.12]) log copies/mL; P = .59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P = .88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART.
Bansi
Loveleen
L
Research Department of Infection and Population Health, University College Medical School, Royal Free Campus, London, United Kingdom. l.bansi@pcps.ucl.ac.uk
Sabin
Caroline
C
Gilson
Richard
R
Gazzard
Brian
B
Leen
Clifford
C
Anderson
Jane
J
Dunn
David
D
Hill
Teresa
T
Fisher
Martin
M
Ainsworth
Jonathan
J
Pillay
Deenan
D
Johnson
Margaret
M
Walsh
John
J
Orkin
Chloe
C
Easterbrook
Philippa
P
Gompels
Mark
M
Phillips
Andrew
A
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir; D017211:Treatment Failure; D016896:Treatment Outcome; D019562:Viral Load; D000099227:Abacavir
D000225:Adenine; D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D063065:Organophosphonates; D000068698:Tenofovir; D000099227:Abacavir